Management of Chronic Hepatitis B Infection
Initial Baseline Evaluation
All adults with chronic hepatitis B (HBsAg positive >6 months) require comprehensive baseline assessment including HBeAg/anti-HBe status, quantitative HBV DNA, liver enzymes, fibrosis staging, and hepatocellular carcinoma screening. 1, 2
Essential Laboratory Testing
- Viral markers: HBeAg, anti-HBe, and quantitative HBV DNA by real-time PCR to determine disease phase and replication status 1, 2
- Liver function panel: Complete blood count, AST/ALT, alkaline phosphatase, GGT, bilirubin, albumin, prothrombin time/INR, and creatinine 1, 2
- Coinfection screening: Anti-HCV, anti-HDV (in injection drug users or high-risk populations), and anti-HIV testing because coinfections accelerate liver disease and alter treatment decisions 3, 1, 2
- Hepatitis A immunity: IgG anti-HAV to identify patients requiring vaccination 1, 2
Fibrosis Assessment
- Non-invasive transient elastography is the preferred initial method for staging liver fibrosis, reserving liver biopsy for indeterminate cases or when additional liver pathology is suspected 1, 2
- Liver biopsy remains most useful in patients with borderline treatment criteria (ALT 1-2× upper limit of normal with HBV DNA >20,000 IU/mL in HBeAg-positive or >2,000 IU/mL in HBeAg-negative patients) 3
Hepatocellular Carcinoma Screening
- Baseline abdominal ultrasound and serum α-fetoprotein should be obtained in all HBsAg-positive patients aged ≥20 years 1, 2
- Ultrasound every 6 months is mandatory for high-risk patients: all cirrhotic patients regardless of HBV DNA level, Asian men >40 years, Asian women >50 years, Africans >20 years, and those with family history of HCC 3, 1, 2
Treatment Indications
Treatment decisions are based on HBeAg status, HBV DNA level, ALT elevation, and presence of cirrhosis. 3, 1, 2
HBeAg-Positive Chronic Hepatitis B
- Treat when HBV DNA ≥20,000 IU/mL AND ALT >2× upper limit of normal sustained for 3-6 months 3, 1, 2
- Patients with HBV DNA >20,000 IU/mL, ALT 1-2× upper limit of normal, and age >40 years should undergo liver biopsy; treat if moderate/severe inflammation or significant fibrosis is present 3
HBeAg-Negative Chronic Hepatitis B
- Treat when HBV DNA ≥2,000 IU/mL AND ALT >2× upper limit of normal 3, 1, 2
- This population requires careful longitudinal evaluation because HBV DNA and ALT levels fluctuate; single measurements are insufficient for treatment decisions 3
Cirrhotic Patients
- All patients with compensated or decompensated cirrhosis and any detectable HBV DNA require immediate antiviral therapy regardless of ALT level or HBeAg status 3, 1, 2
- Peginterferon is contraindicated in decompensated cirrhosis 3
Special Populations Requiring Prophylaxis
- All HBsAg-positive patients must receive antiviral prophylaxis before any immunosuppressive therapy (chemotherapy, anti-CD20 antibodies, TNF-α inhibitors, stem-cell transplantation) even if they are inactive carriers with undetectable HBV DNA, because reactivation can cause fulminant hepatic failure and death 1, 2
- Prophylaxis should start 2-4 weeks prior to immunosuppression and continue for at least 12 months after completion (18 months for rituximab-based regimens) 1, 2
First-Line Antiviral Therapy
Entecavir or tenofovir (disoproxil fumarate or alafenamide) are the only recommended first-line agents because of their high barrier to resistance. 3, 1, 2
Nucleos(t)ide Analogue Selection
- Entecavir 0.5 mg once daily (on empty stomach, 2 hours after and 2 hours before meals) for nucleoside-naïve patients with compensated liver disease 4
- Entecavir 1 mg once daily for lamivudine-resistant patients or those with decompensated liver disease 4
- Tenofovir alafenamide 25 mg once daily with food is preferred over tenofovir disoproxil fumarate in patients with renal impairment or bone disease concerns 5
- Tenofovir disoproxil fumarate 300 mg once daily (without regard to food) is an alternative first-line option 6
- Lamivudine, adefovir, telbivudine, and emtricitabine monotherapy must be avoided due to high resistance rates 3, 1, 2
Peginterferon Considerations
- Peginterferon alfa can be considered for compensated cirrhosis patients in highly selected cases, but risks (side effects, potential liver function deterioration) versus benefits (finite duration, immune-mediated control) must be carefully weighed 3
- Peginterferon is absolutely contraindicated in pregnancy and decompensated cirrhosis 3
- Peginterferon achieves higher rates of HBeAg and HBsAg loss primarily in genotype A infection; sustained response rates after 1-year treatment are only 27-36% for HBeAg-positive and 28% for HBeAg-negative patients 3
Renal Dose Adjustments
- Entecavir: For creatinine clearance 30-49 mL/min give 0.5 mg every 48 hours (or 1 mg once daily for lamivudine-resistant); for 10-29 mL/min give 0.5 mg every 72 hours (or 1 mg every 72 hours); for <10 mL/min or hemodialysis give 0.5 mg every 7 days (or 1 mg every 7 days) after dialysis 4
- Tenofovir alafenamide: No adjustment needed for creatinine clearance ≥15 mL/min or end-stage renal disease on chronic hemodialysis (administer after dialysis); not recommended in end-stage renal disease without hemodialysis 5
- Tenofovir disoproxil fumarate: Requires dose adjustment for creatinine clearance <50 mL/min 6
Follow-Up Monitoring
Patients Not Meeting Treatment Criteria
- Monitor ALT and HBV DNA every 3-6 months, and HBeAg/anti-HBe every 6-12 months to detect transition to treatment-indicated phases 3, 1, 2
- For patients in the "grey zone" (uncertain treatment indication), increase monitoring frequency to ALT and HBV DNA every 1-3 months and HBeAg/anti-HBe every 2-6 months 3
- If ALT rises above upper limit of normal, immediately increase monitoring to every 1-3 months and recheck HBV DNA 3, 1, 2
- Patients over age 40 with persistent ALT elevation warrant closer monitoring due to increased mortality risk from liver disease 3
Verification of Inactive Carrier State
- HBeAg-negative patients with normal ALT and HBV DNA <2,000 IU/mL require ALT testing every 3 months during the first year to verify true inactive carrier status, then every 6-12 months, because 15-35% may develop HBV reactivation over time 3, 2
- More frequent HBV DNA monitoring should be performed if ALT or AST increases above normal 3
Patients on Antiviral Therapy
- Check ALT and quantitative HBV DNA every 6 months to assess virologic response and hepatic inflammation 1, 2
- Rising HBV DNA after initial suppression indicates potential antiviral resistance and requires investigation 1, 2
- Continue monitoring renal function (creatinine) annually, especially in patients on tenofovir 2
Duration of Therapy
- The optimal duration of nucleos(t)ide analogue treatment is unknown 4
- Current guidelines recommend indefinite treatment in cirrhotic patients 3
- For non-cirrhotic HBeAg-positive patients, continue until 1 year after confirmed HBeAg seroconversion 3
- For non-cirrhotic HBeAg-negative patients, continue until HBsAg loss 3
- Withdrawal of nucleos(t)ide analogues almost always results in viral relapse even after years of undetectable HBV DNA 3
Critical Pitfalls and Caveats
Monitoring and Diagnosis
- Never rely on a single HBV DNA or ALT measurement to make treatment decisions; fluctuations are common, especially in HBeAg-negative disease, requiring serial assessments over 3-6 months 3, 2
- Do not assume that inactive carriers are low-risk during immunosuppression; they require prophylaxis because reactivation can be fatal 1, 2
- An HBsAg level of 4,000 IU/mL does not meet the ≤1,000 IU/mL threshold for genotype D inactive-carrier status; serial monitoring is required to clarify disease phase 2
Treatment Selection
- Never use lamivudine, adefovir, telbivudine, or emtricitabine as monotherapy due to high resistance rates 3, 1, 2
- Do not delay cancer treatment while arranging HBV testing or specialist referral 2
- Tenofovir alafenamide or entecavir alone should not be used in HIV/HBV coinfected patients who are not receiving highly active antiretroviral therapy, as this may lead to HIV resistance 4, 5
Post-Treatment Monitoring
- Severe acute exacerbations of hepatitis B can occur after discontinuation of antiviral therapy; monitor hepatic function closely with clinical and laboratory follow-up for at least several months, and consider resuming treatment if indicated 4, 5, 6
- More than 95-99% of adults with acute HBV infection recover spontaneously without antiviral therapy; treatment is reserved for fulminant or severe hepatitis 3
Transmission Prevention and Contact Management
- Screen all household members, sexual partners, and needle-sharing contacts for HBsAg, anti-HBc, and anti-HBs 1, 2
- Vaccinate all susceptible contacts immediately without awaiting serologic results; administer the first vaccine dose at the time of blood draw 1, 2
- Counsel patients that HBV spreads via blood, sexual contact, and perinatal routes; recommend safe-sex practices, avoiding sharing personal items that may be contaminated with blood (toothbrushes, razors), and abstaining from blood, organ, tissue, or semen donation 1, 2
- Clean blood spills with bleach solution 2
- Newborns of HBsAg-positive pregnant women should receive hepatitis B vaccine and hepatitis B immune globulin at birth 2
- All HBsAg-positive patients lacking hepatitis A immunity should receive two doses of hepatitis A vaccine 6-18 months apart to prevent superinfection 3, 1, 2